Show simple item record

FieldValueLanguage
dc.contributor.authorKale, Atharva Rajesh Kumar
dc.date.accessioned2025-01-22T05:26:27Z
dc.date.available2025-01-22T05:26:27Z
dc.date.issued2024en_AU
dc.identifier.urihttps://hdl.handle.net/2123/33544
dc.descriptionIncludes publication
dc.description.abstractDiabetes is a global health burden characterised by β-cell death and loss of function. Islet transplantation is a recognised treatment for patients with Type 1 Diabetes Mellitus (T1DM) and hypoglycaemic unawareness, but broader application is constrained by limited islet survival and function post transplantation. CD47 is a cell surface protein implicated in cellular stress responses, but its role in β-cell function remains relatively unexplored. The metabolic role for CD47 was characterised for the first time in β-cells. It was hypothesized that CD47 limits β-cell function and survival, and it was investigated whether CD47 signalling, or expression could be pharmacologically manipulated to enhance β-cell function and survival in the presence of various exogenous stressors, including hypoxia, hyperglycaemia, and endoplasmic reticulum (ER) stress, which are manifest in the peri-transplant period. CD47 inhibition via genetic deletion, silencing, or antibody blockade (in human islets and MIN6 β-cells) improved insulin protein expression. NOD mice treated with α-CD47 antibody had delayed development of hyperglycaemia. CD47-inhibited mouse islets compared to wildtype (WT, CD47+/+) mouse islets transplanted into diabetic mice significantly improved glucose control. Hypoxia increased CD47 expression while concurrently decreased insulin expression. CD47 inhibition under hypoxia increased insulin and pro-survival protein expression and limited senescence. CD47 inhibition protected MIN6 β-cells from ER stress by limiting the protein expression of ER stress markers (BiP, Ire1α and peif2a). Finally, CD47-silencing in MIN6 β-cells enhanced endothelial cell migration, via paracrine signalling. Overall, this thesis provides key insights into the essential role of CD47 as a novel regulator of islet dysfunction and inhibitor of cytoprotective responses to stress. Limiting CD47 activation may be a potential therapeutic tool in conditions where islet function is inadequate.en_AU
dc.language.isoenen_AU
dc.subjectDiabetesen_AU
dc.subjectType 1 Diabetes Mellitusen_AU
dc.subjectbeta cell signalingen_AU
dc.subjectislet transplantationen_AU
dc.subjectCD47en_AU
dc.subjectTSP1en_AU
dc.titleInvestigating changes in beta cell function by modulating CD47en_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen_AU
usyd.departmentSydney Medical Schoolen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorRogers, Natasha
usyd.include.pubYesen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.